Dysuria therapeutic agents as an independent prognostic factor for the primary recurrence of non-muscle invasive bladder cancer: a propensity score matching study

J Int Med Res. 2021 Aug;49(8):3000605211037478. doi: 10.1177/03000605211037478.


Objective: To investigate if the use of therapeutic agents for dysuria is a risk factor for the primary recurrence of non-muscle invasive bladder cancer (NMIBC).

Methods: First, patients with NMIBC were divided into two groups: the non-recurrence group and the recurrence group. Patient characteristics were compared between both groups. The risk factors of recurrence that were statistically different between the two groups were identified by multivariate analysis. Second, we divided the patients into risk and non-risk groups, and differences in the recurrence-free survival (RFS) between the two groups were analyzed before and after propensity score matching (PSM).

Results: A total of 162 patients were included, with 84 patients in the non-recurrence group and 78 patients in the recurrence group. In the multivariate analysis, the intake of dysuria agents and bacillus Calmette-Guérin (BCG) therapy were independent factors. The RFS results in terms of the intake of dysuria agents were statistically significant before and after PSM analysis, but no factors were significantly different between the BCG and non-BCG groups after PSM.

Conclusions: Therapeutic agents for dysuria might be at an independent risk factor for NMIBC recurrence. This trial is registered with the UMIN Clinical Trials Registry under the number UMIN000036097 (https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno = R000041122).

Keywords: Bladder cancer; dysuria; non-muscle invasive; propensity score matching study; recurrence; residual urine.

MeSH terms

  • Adjuvants, Immunologic
  • Dysuria / etiology
  • Humans
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local / drug therapy
  • Prognosis
  • Propensity Score
  • Urinary Bladder Neoplasms* / drug therapy


  • Adjuvants, Immunologic